Featured
-
-
Original Article |
Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model
- C Weber
- , I Neacsu
- & S T Pleger
-
Original Article
| Open Access
Beneficial effects of selective HDL-raising gene transfer on survival, cardiac remodelling and cardiac function after myocardial infarction in mice
- S C Gordts
- , I Muthuramu
- & B De Geest
-
Review |
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy
- J-S Hulot
- , G Senyei
- & R J Hajjar
-
-
-
-
Review |
Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade
- J Reinkober
- , H Tscheschner
- & P W J Raake
-
-
Review |
Cardiac gene therapy in large animals: bridge from bench to bedside
- K Ishikawa
- , L Tilemann
- & Y Kawase
-
Original Article
| Open Access
Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure
- S Sundararaman
- , T J Miller
- & M S Penn
-
Original Article |
Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo
- J D White
- , D M Thesier
- & C R Bridges
Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure
Prospects for gene transfer for clinical heart failure
Gene therapy for ventricular tachyarrhythmias
Gene delivery technologies for cardiac applications
Targeting S100A1 in heart failure